Association of cancer-associated fibroblasts and survival in malignant ovarian neoplasms

被引：0

作者：

da Silva, Ana Carolline ^{[1
]}

Jammal, Millena Prata ^{[1
]}

Etchebehere, Renata Margarida ^{[2
]}

Candido Murta, Eddie Fernando ^{[1
]}

Nomelini, Rosekeila Simoes ^{[1
]}

机构：

[1] Univ Fed Triangulo Mineiro, Res Inst Oncol IPON, Dept Gynecol & Obstet, BR-38025440 Uberaba, MG, Brazil

[2] Univ Fed Triangulo Mineiro, Surg Pathol Serv, BR-38025440 Uberaba, MG, Brazil

来源：

EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY | 2021年 / 42卷 / 04期

关键词：

Epithelial ovarian cancer; Borderline ovarian tumors; Smooth muscle alphaactin; Fibroblast activation protein-alpha; Tumor microenvironment; Overall survival; ACTIVATION PROTEIN-ALPHA; SMOOTH MUSCLE ACTIN; CARCINOMA-ASSOCIATED FIBROBLASTS; STROMAL MYOFIBROBLASTS; SERINE-PROTEASE; EXPRESSION; TUMOR; FAP; RECURRENCE; MODELS;

D O I：

10.31083/j.ejgo4204118

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Objective: The aims of the study were to compare the stromal immunostaining of smooth muscle alpha-actin (alpha-SMA) and fibroblast activation protein-alpha (FAP) between borderline ovarian tumors and epithelial ovarian cancer, and to evaluate their association in overall survival (OS) and disease-free survival (DFS) in patients with ovarian cancer. Methods: Patients diagnosed with malignant (n = 28) and borderline ovarian tumors (n = 18) were evaluated. Immunohistochemical study of stromal alpha-SMA and FAP was carried out. The comparison of immunostaining between borderline and malignant ovarian tumors was performed using Fisher's exact test. Survival was assessed by the Kaplan-Meier method and the log-rank test. Multivariate analysis was performed by Cox regression. The differences were considered significant for p < 0.05. Results: Evaluating stromal FAP, stronger immunostaining (2 and 3) was more often found in epithelial ovarian cancer than in borderline ovarian tumors (p = 0.0331). There was no statistical significance in the assessment of alpha-SMA. Evaluating only patients with epithelial ovarian cancer, there was a higher OS in patients with stromal alpha-SMA immunostaining 3 (p = 0.017). There was no statistical significance when evaluating OS and DFS in patients with stromal FAP immunostaining, nor evaluating DFS in patients with alpha-SMA stromal immunostaining 3. After multivariate analysis, patients with stromal alpha-SMA immunostaining 3 had higher OS compared to immunostaining 0, 1 or 2 [OR (95% CI) = 0.107 (0.018-0.649), p = 0.015]. Conclusion: Stronger FAP immunostaining was more often found in epithelial ovarian cancer than in borderline ovarian tumors. In epithelial ovarian cancer, there was a higher OS in patients with stromal alpha-SMA immunostaining 3.

引用

页码：782 / 787

页数：6